UPDATE: Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration; Bayer Retains Exclusive Commercialization Rights Outisde US; Regeneron Retains Full US Rights

Regeneron Pharmaceuticals (NASDAQ: REGN ) and Bayer HealthCare today announced an agreement to jointly develop an innovative antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a potential combination therapy with EYLEA® (aflibercept) for the treatment of wet age-related macular degeneration (wet AMD). Preclinical data suggests